Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DJ5B | ISIN: IE00BDGMC594 | Ticker-Symbol: AWK
Tradegate
02.06.25 | 16:14
8,050 Euro
-1,83 % -0,150
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AVADEL PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
AVADEL PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
8,0508,25011:43
8,0508,25011:44

Aktuelle News zur AVADEL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.05.Avadel Pharmaceuticals appoints Susan Rodriguez as COO2
13.05.Avadel appoints new COO to boost narcolepsy drug growth3
AVADEL PHARMACEUTICALS Aktie jetzt für 0€ handeln
13.05.AVADEL PHARMACEUTICALS PLC - 8-K, Current Report1
13.05.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating Officer120DUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 - Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced...
► Artikel lesen
08.05.Avadel Pharmaceuticals plc: Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)72DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
► Artikel lesen
07.05.AVADEL PHARMACEUTICALS PLC - 10-Q, Quarterly Report-
07.05.Avadel Pharmaceuticals GAAP EPS of -$0.051
07.05.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance204-- Generated $52.5 million in net revenue from sales of LUMRYZ, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since...
► Artikel lesen
06.05.AVADEL PHARMACEUTICALS PLC - 8-K, Current Report-
06.05.Avadel wins appeal to expand LUMRYZ trials beyond narcolepsy3
06.05.Avadel gewinnt Berufung zur Ausweitung von LUMRYZ-Studien über Narkolepsie hinaus1
06.05.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction89- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ for...
► Artikel lesen
06.05.Earnings Outlook For Avadel Pharmaceuticals1
06.05.Avadel Pharma gains after appeals court ruling in Lumryz case with Jazz Pharma5
30.04.Avadel Pharmaceuticals plc: Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 74
10.04.Avadel Pharmaceuticals plc: Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)141DUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
► Artikel lesen
08.04.AVADEL PHARMACEUTICALS PLC - 8-K, Current Report1
08.04.Avadel reports steady demand and patent lawsuits2
08.04.Avadel berichtet über stabile Nachfrage und Patentklagen3
25.03.Avadel Pharmaceuticals plc: Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians3
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1